Physician profile
John A Keith
NPI 1073559829
$960.23
in general payments reported to CMS, 2019-2025
14 companies · $279 in 2025
The $279 reported for 2025 was more than what 83% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.03 · 2021: $120 · 2022: $229 · 2023: $172 · 2024: $136 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $587.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $273.54 | 2021-2025 | Qelbree, Qelbree |
| Glaxosmithkline, LLC. | $185.55 | 2022-2025 | Bexsero |
| Corium, LLC | $173.71 | 2021-2025 | Azstarys |
| Pfizer INC. | $95.09 | 2019-2025 | |
| Cranial Technologies, INC | $40.78 | 2022-2023 | Doc Band |
| Merck Sharp & Dohme LLC | $36.44 | 2021-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Sanofi-Aventis U.S. LLC | $28.74 | 2024 | |
| Seqirus USA INC | $27.50 | 2025 | Flucelvax |
| Adlon Therapeutics L.P. | $21.66 | 2021 | |
| Tris Pharma INC | $20.25 | 2025 | Onyda Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $17.34 | 2022 | |
| Krystal Biotech INC | $15.85 | 2024 | Vyjuvek |
| Sanofi Pasteur INC. | $12.86 | 2023 | |
| Ironshore Pharmaceuticals INC. | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Keith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.